Aurinia Pharmaceuticals Inc Clinical Trial Update Transcript
Hello, and welcome to the Aurinia Pharmaceuticals AUDREY update. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to Glenn Schulman. Please go ahead, sir.
Thank you, Kevin, and good afternoon, everyone. Welcome to this afternoon's conference call as we review the top line results of the AUDREY Phase II/III clinical study of VOS for the potential treatment of dry eye syndrome. Joining me from the Aurinia team on the call this afternoon are Mr. Peter Greenleaf, President and CEO; Dr. Neil Solomons, Chief Medical Officer; Mr. Mike Martin, Chief Business Officer; and Mr. Joe Miller, our Chief Financial Officer.
This afternoon, we issued the press release with the top line results from the AUDREY trial, which should be available on our website at www.auriniapharma.com. I'd like to remind everyone that today's call is being
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
